Recent Updates
Recently added Catalysts
AKBA Positive Sentiment

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

Tuesday, May 14, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Akebia Therapeutics announced that CEO John Butler will participate in a fireside chat at the 2nd Annual HCW Bioconnect Investor Conference on May 20, 2024. The event will take place in New York, and a webcast of the presentation will be available for 30 days on the company's website. This engagement underscores Akebia's focus on improving the lives of those affected by kidney disease.
Price reaction · baseline $1.29 (2024-05-13 close) · hit after-hours · clean, no other AKBA news in the window
day 0 close · peak
-4.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Akebia Therapeutics is actively engaging with investors.
  • The participation in the conference highlights the company's commitment to kidney disease.
  • The CEO's involvement suggests confidence in the company's future.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1%
120-day peak, hindsight
Typical move
8%
average across 4 past catalysts
Lead asset
ferric
Phase 3 · Anemia of Chronic Kidney Disease

Full Press Release Details

CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA ), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will participate in a fireside chat at the 2 nd Annual HCW Bioconnect Investor Conference on Monday, May 20 th , 2024 at 3:00 p.m. ET .
The 2 nd Annual HCW Bioconnect Investor Conference will take place in New York, NY on May 20, 2024 .
A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.
About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release.
Akebia Therapeutics Contact Mercedes Carrasco [email protected]

Frequently Asked Questions

When will Akebia's CEO speak at the conference?

John Butler will participate in a fireside chat on May 20, 2024.

Where is the HCW Bioconnect Investor Conference held?

The conference will take place in New York, NY.

How can I access the conference webcast?

The webcast will be available on Akebia's website for 30 days post-conference.

What is the focus of Akebia Therapeutics?

Akebia aims to improve the lives of people impacted by kidney disease.

ShareAdd on Google
Tags: AKBA Viatris Investor Conferences Healthcare Akebia Therapeutics kidney disease investor conference John Butler HCW Bioconnect
Last updated: May 14, 2024

Biotech snapshot

Cash runway
$156M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ferricPhase 3
Anemia of Chronic Kidney Disease →

Catalyst track record

+1%
best trade around AKBA's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AKBA.

See every catalyst's timing & PoA →